Featured Research

from universities, journals, and other organizations

Testosterone therapy improves memory in postmenopausal women, preliminary study finds

Date:
June 7, 2011
Source:
The Endocrine Society
Summary:
Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds.

Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds.

The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston.

"Women have a higher risk of developing dementia compared to men," said Sonia Davison, MD, PhD, the study's lead investigator and a postdoctoral research fellow at Monash University, Melbourne. "These results offer a potential therapy, where none currently exists, to slow cognitive decline in women."

The researchers compared a control group of 30 women who received no treatment with a group of nine healthy women in early menopause (ages 47 to 60) who knowingly received the testosterone spray on their skin. The spray dose returned testosterone levels in the blood to those typical of young women of childbearing age, according to Davison. All of the treated women were receiving a stable dose of non-oral hormone replacement therapy.

All women underwent testing of cognitive function with a battery of computerized tests that can detect even small changes in cognitive performance, Davison said. The researchers tested subjects' memory through their ability to recall items from a grocery list read aloud to them -- a test of verbal learning and memory -- and through their performance on tests of visual learning and memory. Cognitive testing occurred at the beginning and end (week 26) of the study.

At the start of the study the two groups did not differ significantly in their cognitive test results. After 26 weeks the untreated controls showed no significant differences between their initial and final test results, the authors found. The testosterone-treated group, however, improved their verbal learning and memory, as found on the shopping list test, Davison reported.

"This is exciting in that the testosterone-treated women were all healthy, with no cognitive impairment, and there was a definite treatment effect of the testosterone spray," Davison said. "Testosterone may play a protective role against dementia."

She said their results need confirmation in a randomized, controlled clinical trial.

The following organizations helped finance this study: the National Health and Medical Research Council of Australia, the Royal Australasian College of Physicians Research and Education Foundation (Vincent Fairfax Family Foundation fellowship) and FemPharm in Australia, which makes the testosterone spray for women.


Story Source:

The above story is based on materials provided by The Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

The Endocrine Society. "Testosterone therapy improves memory in postmenopausal women, preliminary study finds." ScienceDaily. ScienceDaily, 7 June 2011. <www.sciencedaily.com/releases/2011/06/110606142352.htm>.
The Endocrine Society. (2011, June 7). Testosterone therapy improves memory in postmenopausal women, preliminary study finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/06/110606142352.htm
The Endocrine Society. "Testosterone therapy improves memory in postmenopausal women, preliminary study finds." ScienceDaily. www.sciencedaily.com/releases/2011/06/110606142352.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins